Investment in the cardiometabolic field has been flat over the past five years. The number of private financing rounds has fallen over that time, but the amounts raised have been steady. Interest in the field seems to be increasing though, with smaller companies finding gaps in the market for new mechanisms in niche indications.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?